ezetimibe has been researched along with Benign Neoplasms in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Frikke-Schmidt, R; Kobberø Lauridsen, B; Nordestgaard, BG; Stender, S; Tybjærg-Hansen, A | 1 |
| Basta, N; Bolin, K; Busch-Sørensen, M; Egstrup, K; Emneus, M; Green, A; Iachina, M; Kent, C; Kesäniemi, YA; McNally, R; Pedersen, TR; Ramey, DR; Ray, S; Stavem, K; Willenheimer, R | 1 |
| Baigent, C; Califf, R; Clare, R; Collins, R; Emberson, J; Landray, M; Peto, R | 1 |
| Curfman, GD; D'Agostino, RB; Drazen, JM; Morrissey, S; Ware, JH | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R | 1 |
| Fleming, TR | 1 |
| Cox, A | 1 |
| Nissen, SE | 1 |
| Blazing, MA; Califf, RM; Harrington, RA | 1 |
| Nissen, SE; Taylor, AJ | 1 |
| Drazen, JM; Wood, AJ | 1 |
| Kim, PS; Rosenblatt, M | 1 |
| Boyden, T; Khanderia, U; Regal, RE; Rubenfire, M | 1 |
| Prasad, V; Vandross, A | 1 |
2 review(s) available for ezetimibe and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
The ezetimibe controversy: implications for clinical practice.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Plaque, Atherosclerotic | 2011 |
2 trial(s) available for ezetimibe and Benign Neoplasms
| Article | Year |
|---|---|
Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Neoplasms; Registries; Retrospective Studies; Risk Assessment; Simvastatin; Survival Rate; Time Factors | 2014 |
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticholesteremic Agents; Aortic Valve Stenosis; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Bypass; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Kaplan-Meier Estimate; Male; Neoplasms; Simvastatin; Treatment Outcome | 2008 |
12 other study(ies) available for ezetimibe and Benign Neoplasms
| Article | Year |
|---|---|
Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Denmark; Ezetimibe; Female; Genetic Variation; Humans; Hypercholesterolemia; Male; Membrane Proteins; Membrane Transport Proteins; Mendelian Randomization Analysis; Middle Aged; Neoplasms; Proportional Hazards Models; Risk Assessment; Risk Factors | 2017 |
Analyses of cancer data from three ezetimibe trials.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin | 2008 |
Ezetimibe and cancer--an uncertain association.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin | 2008 |
Identifying and addressing safety signals in clinical trials.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin | 2008 |
Hypercholesterolaemia: Clarifications from adverse drug reactions agency.
Topics: Anticholesteremic Agents; Azetidines; England; Ezetimibe; Humans; Hypercholesterolemia; Neoplasms; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2008 |
Analyses of cancer data from three ezetimibe trials.
Topics: Anticholesteremic Agents; Azetidines; Data Interpretation, Statistical; Ezetimibe; Humans; Hypercholesterolemia; Neoplasms; Randomized Controlled Trials as Topic; Risk | 2009 |
Premature release of data from clinical trials of ezetimibe.
Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Databases as Topic; Drug Approval; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Registries; Simvastatin; United States | 2009 |
Preliminary observations from preliminary trial results: have we finally had enough?
Topics: Adult; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Surgical Procedures; Ezetimibe; Heart Failure; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Reperfusion Injury; Research Design; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Don't mess with the DSMB.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States | 2010 |
Ezetimibe: excess cancer incidence in a comparative trial.
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Incidence; Neoplasms | 2010 |
More on DSMBs.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Drug Industry; Ezetimibe; Humans; Neoplasms; Simvastatin; United States | 2011 |
Cardiovascular primary prevention: how high should we set the bar?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin | 2012 |